JP2017533969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533969A5 JP2017533969A5 JP2017544552A JP2017544552A JP2017533969A5 JP 2017533969 A5 JP2017533969 A5 JP 2017533969A5 JP 2017544552 A JP2017544552 A JP 2017544552A JP 2017544552 A JP2017544552 A JP 2017544552A JP 2017533969 A5 JP2017533969 A5 JP 2017533969A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- naca
- agent according
- prophylactic agent
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076594P | 2014-11-07 | 2014-11-07 | |
| US62/076,594 | 2014-11-07 | ||
| PCT/US2015/059589 WO2016073931A1 (en) | 2014-11-07 | 2015-11-06 | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019191044A Division JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533969A JP2017533969A (ja) | 2017-11-16 |
| JP2017533969A5 true JP2017533969A5 (https=) | 2018-04-19 |
Family
ID=55909913
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12472157B2 (https=) |
| EP (2) | EP3214934A4 (https=) |
| JP (5) | JP2017533969A (https=) |
| KR (3) | KR20170109527A (https=) |
| CN (2) | CN108498495A (https=) |
| AU (5) | AU2015342831B2 (https=) |
| BR (1) | BR112017009584A2 (https=) |
| CA (1) | CA2967327C (https=) |
| HK (1) | HK1252822A1 (https=) |
| RU (1) | RU2711913C2 (https=) |
| WO (2) | WO2016073931A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| US12472157B2 (en) | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
| WO2016077467A1 (en) | 2014-11-11 | 2016-05-19 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| EP3684756A4 (en) | 2017-09-20 | 2020-10-28 | NaCuity Pharmaceuticals, Inc. | SYNTHESIS OF N-ACETYLCYSTEIN AMIDE AND ITS DERIVATIVES |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190151271A1 (en) * | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| CA3104209A1 (en) * | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| CN109096161B (zh) * | 2018-08-24 | 2020-10-27 | 武汉远大弘元股份有限公司 | 一种n-乙酰半胱氨酸的制备方法 |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| EP3908271A4 (en) | 2019-01-11 | 2022-10-26 | NaCuity Pharmaceuticals, Inc. | N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT |
| AU2021209953B2 (en) * | 2020-01-24 | 2024-08-22 | Nacuity Pharmaceuticals, Inc. | Prodrug for the treatment of disease and injury of oxidative stress |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3252866A (en) | 1965-06-28 | 1966-05-24 | Mead Johnson & Co | 2-hydrocarbon substituted-amido mercaptopropionamides in hair waving compositions and processes |
| US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US20030027745A1 (en) | 2001-06-13 | 2003-02-06 | Repine John E. | Diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same |
| BE1014949A3 (fr) | 2001-08-14 | 2004-07-06 | Probiox | Procede de detection de stress oxydant et trousse pour sa mise en oeuvre. |
| US20060211628A1 (en) | 2002-08-02 | 2006-09-21 | Daphne Atlas | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| US7795203B2 (en) | 2002-09-30 | 2010-09-14 | Babizhayev Mark A | Method for topical treatment of eye disease and composition and device for said treatment |
| JP2005350405A (ja) | 2004-06-11 | 2005-12-22 | Shiseido Co Ltd | 重合抑制剤および即時型黒化防止用皮膚外用剤 |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| CN101232877A (zh) * | 2005-04-21 | 2008-07-30 | 格伦·A·戈尔茨坦 | 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺） |
| US20090234011A1 (en) * | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| JP4840804B2 (ja) | 2006-01-20 | 2011-12-21 | 学校法人慶應義塾 | 酸化ストレスの判定方法 |
| WO2010048716A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US20120150029A1 (en) | 2008-12-19 | 2012-06-14 | University Of Miami | System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography |
| US9173423B2 (en) | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
| WO2011044230A2 (en) | 2009-10-06 | 2011-04-14 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions |
| EP2397125A1 (en) | 2010-06-15 | 2011-12-21 | Histocell, S.L. | Antioxidant composition |
| US20120142550A1 (en) | 2010-12-06 | 2012-06-07 | Zehnder James L | Vanin 1 as a Peripheral Blood Oxidative Stress Sensor |
| WO2013138744A1 (en) | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| CA2871774C (en) * | 2012-04-26 | 2021-05-18 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| EP2928562A4 (en) | 2012-12-06 | 2016-06-22 | Stealth Peptides Int Inc | PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE |
| US20150328337A1 (en) | 2012-12-19 | 2015-11-19 | The Johns Hopkins University | Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase |
| US9763902B2 (en) | 2014-03-28 | 2017-09-19 | Nacuity Pharmaceuticals, Inc | Method for preparation of N-acetyl cysteine amide |
| US12472157B2 (en) | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
| WO2016077467A1 (en) | 2014-11-11 | 2016-05-19 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| JP7418958B2 (ja) | 2016-03-17 | 2024-01-22 | チオジェネシス セラピューティクス， インコーポレイテッド | システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療 |
| EP3684756A4 (en) | 2017-09-20 | 2020-10-28 | NaCuity Pharmaceuticals, Inc. | SYNTHESIS OF N-ACETYLCYSTEIN AMIDE AND ITS DERIVATIVES |
| JP7208982B2 (ja) | 2017-09-20 | 2023-01-19 | チオジェネシス セラピューティクス， インコーポレイテッド | システアミン感受性障害の治療方法 |
| WO2019060704A1 (en) | 2017-09-22 | 2019-03-28 | University Of Florida Research Foundation | DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| WO2019097434A1 (en) | 2017-11-17 | 2019-05-23 | Mahmood Piraee | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders |
| US20190151271A1 (en) | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| CN108618993B (zh) | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
| WO2020102810A1 (en) | 2018-11-16 | 2020-05-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive gel eye drop for ocular delivery of cysteamine |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| EP3908271A4 (en) | 2019-01-11 | 2022-10-26 | NaCuity Pharmaceuticals, Inc. | N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT |
-
2015
- 2015-11-06 US US15/523,665 patent/US12472157B2/en active Active
- 2015-11-06 WO PCT/US2015/059589 patent/WO2016073931A1/en not_active Ceased
- 2015-11-06 KR KR1020177015227A patent/KR20170109527A/ko not_active Ceased
- 2015-11-06 KR KR1020227009489A patent/KR20220039853A/ko not_active Ceased
- 2015-11-06 RU RU2017119230A patent/RU2711913C2/ru active
- 2015-11-06 US US15/524,636 patent/US20180296503A1/en not_active Abandoned
- 2015-11-06 BR BR112017009584A patent/BR112017009584A2/pt not_active Application Discontinuation
- 2015-11-06 KR KR1020237036499A patent/KR20230152177A/ko not_active Ceased
- 2015-11-06 AU AU2015342831A patent/AU2015342831B2/en active Active
- 2015-11-06 EP EP15857309.7A patent/EP3214934A4/en not_active Ceased
- 2015-11-06 CA CA2967327A patent/CA2967327C/en active Active
- 2015-11-06 EP EP21217485.8A patent/EP4000612A1/en active Pending
- 2015-11-06 JP JP2017544552A patent/JP2017533969A/ja active Pending
- 2015-11-06 CN CN201810698779.7A patent/CN108498495A/zh active Pending
- 2015-11-06 WO PCT/US2015/059418 patent/WO2016073829A2/en not_active Ceased
- 2015-11-06 CN CN201580072224.6A patent/CN107426997A/zh active Pending
-
2018
- 2018-09-20 HK HK18112150.1A patent/HK1252822A1/zh unknown
-
2019
- 2019-10-18 JP JP2019191044A patent/JP2020023549A/ja active Pending
- 2019-11-07 AU AU2019261762A patent/AU2019261762B2/en active Active
-
2021
- 2021-09-06 AU AU2021225263A patent/AU2021225263B2/en active Active
- 2021-09-10 JP JP2021147283A patent/JP2021193119A/ja active Pending
-
2023
- 2023-08-04 JP JP2023127716A patent/JP2023145734A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200436A patent/AU2024200436A1/en not_active Abandoned
-
2025
- 2025-07-30 JP JP2025126989A patent/JP2025160381A/ja active Pending
-
2026
- 2026-01-05 AU AU2026200033A patent/AU2026200033A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533969A5 (https=) | ||
| JP2020023549A5 (https=) | ||
| JP2023145734A5 (https=) | ||
| RU2017119230A (ru) | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| MX2020014000A (es) | Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. | |
| RU2009148288A (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
| NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
| IN2014MN01706A (https=) | ||
| AU2012284627A8 (en) | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans | |
| HRP20192133T1 (hr) | Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze | |
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| JP2015038135A5 (https=) | ||
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2017506624A5 (https=) | ||
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| MX2010003441A (es) | Formulaciones galenicas de alisquireno y valsartan. | |
| PL2205279T3 (pl) | Farmaceutyczna kombinacja aliskirenu i walsartanu | |
| ME02474B (me) | Terapijski režimi | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| RU2020123405A (ru) | Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| WO2015183984A3 (en) | Therapeutic compositions including tocopherol and uses thereof |